{"id":55869,"date":"2023-04-17T08:04:35","date_gmt":"2023-04-17T06:04:35","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\/"},"modified":"2023-04-17T08:04:35","modified_gmt":"2023-04-17T06:04:35","slug":"akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\/","title":{"rendered":"Akthelia Pharmaceuticals and the University of Iceland Secure a \u20ac6M EU Horizon Grant to Combat Antimicrobial Resistance (AMR)"},"content":{"rendered":"
\n

\nCollaborative IN-ARMOR project aims to advance novel innate immune system inducers for a healthier future<\/i><\/b><\/p>\n

<\/a><\/p>\n

REYKJAVIK, Iceland–(BUSINESS WIRE)–#AMR<\/a>–Akthelia Pharmaceuticals, a biopharma company, with a first-in-class immunotherapeutic approach, and the University of Iceland, are proud to announce the successful joint award of a \u20ac6 million EU Horizon Grant to fund the groundbreaking IN-ARMOR project. The project seeks to address antimicrobial resistance (AMR), a major global health threat identified by the World Health Organization (WHO) as one of the top 10 health challenges of our time.<\/p>\n

\nAMR and multi-drug resistance contribute to over 5 million deaths per year, with the potential to give rise to the next global pandemic as ‘pan-drug’ resistant strains emerge. As traditional antibiotics lose effectiveness, alternative therapeutic approaches are urgently needed.<\/p>\n

\n“We are thrilled that our cutting-edge technology, developed in collaboration with the University of Iceland, has received this prestigious grant,” said Egill Masson, CEO of Akthelia Pharma, “The IN-ARMOR project focuses on novel immune system inducers and is a testament to the potential of our approach to address the global challenge of antimicrobial resistance. The funding propels our ground-breaking research to address not only infections caused by bacteria but also inflammation and the challenge of viral and fungal infections, where fewer treatment options exist.”<\/p>\n

\n“I am delighted to collaborate with Akthelia Pharmaceuticals on this critical initiative,” commented Professor Gudmundur Gudmundsson, Professor of Cell Biology at the University of Iceland and leading authority on innate immunology, “By focusing on enhancing innate immunology, we have the opportunity to move beyond traditional antibiotics towards next generation therapies that could revolutionize the way we combat antimicrobial resistance, ultimately protecting countless lives worldwide.”<\/p>\n

\nThe IN-ARMOR project brings together nine universities, research institutes, and seven medical and industry partners across nine EU countries. The project’s goal is to introduce a novel class of immune system inducers to enhance the body’s innate microbial defense mechanisms, combating AMR and reducing the incidence of 13 of the most dangerous infections, including two of the top three priority-1 infections. Horizon Europe is the EU\u2019s key funding program for research and innovation with a budget of \u20ac95.5 billion.<\/p>\n

\nEmploying computer-aided drug design and in-silico approaches, alongside a nanotech-based drug delivery system, IN-ARMOR will optimize an existing drug platform for its first target indication. The therapy will undergo pre-clinical validation for safety and efficacy, meeting all investigational medicinal product requirements.<\/p>\n

\nUpon completion, IN-ARMOR will advance to clinical validation, with the potential to save over 4 million lives worldwide and significantly reduce the burden of antibiotic development, leading to long-term cost reduction impact of \u20ac107BN and reduction in global disease burden of 97 million DALYs.<\/p>\n

\nAkthelia Pharmaceuticals is committed to addressing the global threat of antimicrobial resistance and believes that the IN-ARMOR project is a vital step towards a healthier future.<\/p>\n

\nABOUT AKTHELIA PHARMACEUTICALS<\/b><\/p>\n

\nAkthelia Pharmaceuticals is a preclinical-stage biopharma company with a next-generation immunotherapeutic strategy to upregulate the innate immunology of epithelial surfaces. This novel approach has application potential to many areas of medicine and addresses the growing threat of antibiotic bacterial resistance (AMR) worldwide.<\/p>\n

\nAkthelia\u2019s lead therapeutic program upregulates the innate immunology in the GI tract, blocking leakage of microbiota to improve outcomes in cancer care through reducing the risk of neutropenia, a common and severe complication in chemotherapy and immunocompromised patients.<\/p>\n

Contacts<\/b> <\/p>\n

\nEgill Masson
\n
CEO
\n
egill.masson@aktheliapharma.com<\/a><\/p>\n

\nAkthelia Pharmaceuticals
\n
Grandagar\u00f0i 16
\n
101 Reykjavik
\n
Iceland<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Collaborative IN-ARMOR project aims to advance novel innate immune system inducers for a healthier future REYKJAVIK, Iceland–(BUSINESS WIRE)–#AMR–Akthelia Pharmaceuticals, a biopharma company, with a first-in-class immunotherapeutic approach, and the University of Iceland, are proud to announce the successful joint award of a \u20ac6 million EU Horizon Grant to fund the groundbreaking IN-ARMOR project. The project … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55869","6":"format-standard","7":"category-industry"},"yoast_head":"\nAkthelia Pharmaceuticals and the University of Iceland Secure a \u20ac6M EU Horizon Grant to Combat Antimicrobial Resistance (AMR) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Akthelia Pharmaceuticals and the University of Iceland Secure a \u20ac6M EU Horizon Grant to Combat Antimicrobial Resistance (AMR) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Collaborative IN-ARMOR project aims to advance novel innate immune system inducers for a healthier future REYKJAVIK, Iceland–(BUSINESS WIRE)–#AMR–Akthelia Pharmaceuticals, a biopharma company, with a first-in-class immunotherapeutic approach, and the University of Iceland, are proud to announce the successful joint award of a \u20ac6 million EU Horizon Grant to fund the groundbreaking IN-ARMOR project. The project ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-17T06:04:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230416005038\/en\/1764802\/21\/Akthelia_Logo_Wide_1000px.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Akthelia Pharmaceuticals and the University of Iceland Secure a \u20ac6M EU Horizon Grant to Combat Antimicrobial Resistance (AMR)\",\"datePublished\":\"2023-04-17T06:04:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\\\/\"},\"wordCount\":576,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230416005038\\\/en\\\/1764802\\\/21\\\/Akthelia_Logo_Wide_1000px.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\\\/\",\"name\":\"Akthelia Pharmaceuticals and the University of Iceland Secure a \u20ac6M EU Horizon Grant to Combat Antimicrobial Resistance (AMR) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230416005038\\\/en\\\/1764802\\\/21\\\/Akthelia_Logo_Wide_1000px.jpg\",\"datePublished\":\"2023-04-17T06:04:35+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230416005038\\\/en\\\/1764802\\\/21\\\/Akthelia_Logo_Wide_1000px.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230416005038\\\/en\\\/1764802\\\/21\\\/Akthelia_Logo_Wide_1000px.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Akthelia Pharmaceuticals and the University of Iceland Secure a \u20ac6M EU Horizon Grant to Combat Antimicrobial Resistance (AMR)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Akthelia Pharmaceuticals and the University of Iceland Secure a \u20ac6M EU Horizon Grant to Combat Antimicrobial Resistance (AMR) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\/","og_locale":"en_US","og_type":"article","og_title":"Akthelia Pharmaceuticals and the University of Iceland Secure a \u20ac6M EU Horizon Grant to Combat Antimicrobial Resistance (AMR) - Pharma Trend","og_description":"Collaborative IN-ARMOR project aims to advance novel innate immune system inducers for a healthier future REYKJAVIK, Iceland–(BUSINESS WIRE)–#AMR–Akthelia Pharmaceuticals, a biopharma company, with a first-in-class immunotherapeutic approach, and the University of Iceland, are proud to announce the successful joint award of a \u20ac6 million EU Horizon Grant to fund the groundbreaking IN-ARMOR project. The project ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-17T06:04:35+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230416005038\/en\/1764802\/21\/Akthelia_Logo_Wide_1000px.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Akthelia Pharmaceuticals and the University of Iceland Secure a \u20ac6M EU Horizon Grant to Combat Antimicrobial Resistance (AMR)","datePublished":"2023-04-17T06:04:35+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\/"},"wordCount":576,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230416005038\/en\/1764802\/21\/Akthelia_Logo_Wide_1000px.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\/","url":"https:\/\/pharma-trend.com\/en\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\/","name":"Akthelia Pharmaceuticals and the University of Iceland Secure a \u20ac6M EU Horizon Grant to Combat Antimicrobial Resistance (AMR) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230416005038\/en\/1764802\/21\/Akthelia_Logo_Wide_1000px.jpg","datePublished":"2023-04-17T06:04:35+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230416005038\/en\/1764802\/21\/Akthelia_Logo_Wide_1000px.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230416005038\/en\/1764802\/21\/Akthelia_Logo_Wide_1000px.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/akthelia-pharmaceuticals-and-the-university-of-iceland-secure-a-e6m-eu-horizon-grant-to-combat-antimicrobial-resistance-amr\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Akthelia Pharmaceuticals and the University of Iceland Secure a \u20ac6M EU Horizon Grant to Combat Antimicrobial Resistance (AMR)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55869","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55869"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55869\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55869"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55869"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55869"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}